A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.
It is the first time that a Phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.
The trial was led in the UK by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 64 research centres worldwide, including the University of Oxford.
Researchers randomised 436 patients with aggressive, inoperable malignant melanoma to receive either an injection of the viral therapy, called Talimogene Laherparepvec, or a control immunotherapy.
Some 16.3% of the group given Talimogene Laherparepvec – known as T-VEC – showed a durable treatment response of more than six months, compared with 2.1% given the control treatment.
Some patients had a response extending past three years, a mark oncologists often use as a proxy for cure in immunotherapy.
Importantly, responses to treatment were most pronounced in patients with less advanced cancers (stage IIIB, IIIC, IVM1a) and those who had yet to receive any treatment – underlining the potential benefits of T-VEC as a first-line treatment for metastatic melanoma which cannot be surgically removed.
Patients with stage III and early stage IV melanoma treated with T-VEC – a total of 163 people – lived an average of 41 months. This compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.
The trial was funded by the manufacturer of T-VEC, Amgen, and is published in the Journal of Clinical Oncology.
T-VEC is a modified form of herpes simplex virus type-1 which multiplies inside cancer cells and bursts them from within. It has been genetically engineered to produce a molecule called GM-CSF, which stimulates the immune system to attack and destroy the tumour.
T-VEC is one of a new wave of virus-based drugs to show benefits in cancer trials, and is now the first to do so in a major randomised, controlled Phase III trial.
The virus has been modified to remove two key genes, called ICP34.5 and ICP47, so that it can’t replicate within healthy cells. Normal cells detect and destroy T-VEC before it can cause damage – but it replicates easily in cancer cells because their infection defences are compromised by genetic errors.
UK trial leader Professor Kevin Harrington, Professor of Biological Cancer Therapies at the ICR and Honorary Consultant at The Royal Marsden, said: “There is increasing excitement over the use of viral treatments like T-VEC for cancer, because they can launch a two-pronged attack on tumours – both killing cancer cells directly and marshalling the immune system against them. And because viral treatment can target cancer cells specifically, it tends to have fewer side-effects than traditional chemotherapy or some of the other new immunotherapies.
“Our study showed that T-VEC can deliver a significant, durable benefit for people with melanoma. It is encouraging that the treatment had such a clear benefit for patients with less advanced cancers – ongoing studies are evaluating if it can become a first-line treatment for more aggressive melanomas and advanced disease.”
The Latest on: Viral immunotherapy
via Google News
The Latest on: Viral immunotherapy
- Candel Therapeutics Appoints Sandra E. Poole as Chief Operating Officeron January 10, 2020 at 4:07 am
NEEDHAM, Mass., Jan. 10, 2020 /PRNewswire/ -- Candel Therapeutics, a leader in developing viral immunotherapies across multiple tumor indications, announced today the appointment of Sandra E. Poole as ...
- Global Viral Vector and Plasmid DNA Manufacturing Market Will Grow to USD Million By 2027on January 9, 2020 at 11:18 pm
Viral Infections, and Immunotherapy): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 – 2027”. According to the report, the global viral vector and plasmid DNA manufacturing ...
- Immuneering Strengthens Executive Team With Appointment of Howard L. Kaufman, M.D., as Head of Research and Developmenton January 9, 2020 at 7:40 am
Cancer immunotherapy leader joins Immuneering’s executive team to apply the company’s Disease Cancelling Technology to immuno-oncology ...
- The New Gilead Is Shaping Upon January 9, 2020 at 2:34 am
HIV and Emerging Viral Infections, and John Sundy, SVP Inflammation and Respiratory Diseases. CFO Washington also attended for either her last or penultimate time. The three engines for Gilead to ...
- OncoMyx Therapeutics Announces Formation of Scientific Advisory Boardon January 8, 2020 at 10:00 pm
PHOENIX--(BUSINESS WIRE)--#biotech--OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced today the formation of its ... The McFadden lab pioneered the field of viral ...
- Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancerson January 6, 2020 at 9:30 pm
capabilities Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations First patients enrolled in two Phase 1 ...
- Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancerson January 6, 2020 at 4:35 pm
This is another step closer towards the realization of an AI-driven individualized immunotherapy for each patient. Our unique partnership with Transgene enables us to leverage its significant clinical ...
- Rational design of universal immunotherapy for TfR1-tropic arenaviruseson January 3, 2020 at 2:16 am
However, despite the fact that all pathogenic arenaviruses from South America utilize transferrin receptor 1 (TfR1) as a cellular receptor, their viral glycoproteins are highly diversified, impeding ...
- UAB gets grant for first in-human study in type of pediatric brain tumor treatmenton January 1, 2020 at 5:15 pm
Standard therapy, like chemotherapy and radiation, can harm a child’s developing brain, UAB said, which is why viral immunotherapy is important for treating kids. Viral immunotherapy can offer a ...
- Super-soldier T-cells fight cancer better after a transformational DNA deliveryon December 29, 2019 at 6:06 pm
Viruses insert their own viral DNA into host cells alongside ... In my opinion, the cancer immunotherapy community needs to expand beyond simple assessments such as efficiency and cell survival ...
via Bing News